Stereoselective synthesis of a novel 2-aza-7-oxabicyclo[3.3.0]octane as neurokinin-1 receptor antagonist

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 24, 2007, Pages 6887-6890

  Shishido, Yuji ^a   Ito, Fumitaka ^a   Morita, Hiromasa ^a   Ikunaka, Masaya ^a  

^a PFIZER INC   (United States)

Author keywords

1,3 Dipolar cycloaddition; Antagonist; Neurokinin 1; NK 1 antagonist

Indexed keywords

4 [N (2 METHOXY 5 TRIFLUOROMETHOXYBENZYL)AMINO] 3 PHENYL 2 AZA 7 OXABICYCLO[3.3.O]OCTANE; CAPSAICIN; NEUROKININ 1 RECEPTOR ANTAGONIST; OCTANE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL LINE; CONTROLLED STUDY; CYCLOADDITION; DISEASE MODEL; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EXTRAVASATION; GUINEA PIG; HUMAN; HUMAN CELL; IC 50; NONHUMAN; NUCLEAR OVERHAUSER EFFECT; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; REACTION ANALYSIS; RECEPTOR AFFINITY; STEREOCHEMISTRY; STRUCTURE ANALYSIS; URETER;

ANIMALS; AZA COMPOUNDS; CALCIUM CHANNELS; EMETICS; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; OCTANES; PROTEIN BINDING; RECEPTORS, NEUROKININ-1; STEREOISOMERISM;

CAVIA;

EID: 35848940252     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.10.010     Document Type: Article

References (26)

1. Gale J.D., O'Neill B.T., and Humphrey J.M. Expert Opin. Ther. Patents 11 (2001) 1837
2. Lecci A., and Maggi C.A. Expert Opin. Ther. Targets 7 (2003) 342
3. Albert J.S. Expert Opin. Ther. Targets 14 (2004) 1421
4. Hale J.J., Mills S.G., MacCoss M., Finke P.E., Cascieri M.A., Sadowski S., Ber E., Chicchi G.G., Kurtz M., Metzger J., Eirmann G., Tsou N.N., Tattersall F.D., Rupniak N.M.J., Williams A.R., Rycroft W., Hargreaves R., and MacIntyre D.E. J. Med. Chem. 41 (1998) 4607
5. Ito, F.; Kondo, H.; Shimada, K.; Nakane, M.; Lowe, J. A. III; Rosen, T. J.; Yang, B. V. WO 9221677 A1.
6. Desai M.C., Lefkowitz S.L., Bryce D.K., and McLean S. Bioorg. Med. Chem. Lett. 4 (1994) 1865
7. Harrison T., Williams B.J., Swain C.J., and Ball R.G. Bioorg. Med. Chem. Lett. 4 (1994) 2545
8. Harrison T., Owens A.P., Williams B.J., Swain C.J., Baker R., Hutson P.H., Sadowski S., and Cascieri M.A. Bioorg. Med. Chem. Lett. 5 (1995) 209
9. Hale J.J., Mills S.G., MacCoss M., Shah S.K., Qi H., Mathre D.J., Cascieri M.A., Sadowski S., Strader C.D., MacIntyre D.E., and Metzger J.M. J. Med. Chem. 39 (1996) 1760
10. Ashwood M.S., Cottrell I.F., and Davies A.J. Tetrahedron: Asymmetry 8 (1997) 957
11. Ladduwahetty T., Baker R., Cascieri M.A., Chambers M.S., Haworth K., Keown L.E., MacIntyre D.E., Metzger J.M., Owen S., Rycroft W., Sadowski S., Seward E.M., Shepheard S.L., Swain C.J., Tattersall F.D., Watt A.P., Williamson D.W., and Hargreaves R.J. J. Med. Chem. 39 (1996) 2907
12. Williams B.J., Cascieri M.A., Chicchi G.G., Harrison T., Owens A.P., Own S.N., Rupniak N.M.J., Tattersall D.F., Williams A., and Swain C.J. Bioorg. Med. Chem. Lett. 12 (2002) 2719
13. Desai M.C., Lefkowitz S.L., Thadeio P.F., Longo K.P., and Snider R.M. J. Med. Chem. 35 (1992) 4911
14. Padwa A., and Ku H. J. Org. Chem. 44 (1979) 255
15. Woller P.B., and Cromwell N.K. J. Org. Chem. 35 (1970) 888
16. Nakamura I., and Harada K. Heterocycles 9 (1978) 473
17. Mori K., Tominaga M., Takigawa T., and Matsui M. Synthesis (1973) 790
18. O-protection of diol 15a using TBDMS-Cl, N-protection using Cbz-Cl followed by O-deprotection under acidic condition also provided 15b in a higher yield.
19. Carlock J.I., and Mack M.P. Tetrahedron Lett. 9 (1978) 473
20. Levin J.I., Turos E., and Weinreb S.M. Synth. Commun. 12 (1982) 989
21. 1H NMR analysis after esterification of 19 using trimethylsilyldiazomethane.
22. Carlsen P.H.J., Katsuki T., Martin V.S., and Sharpless K.B. J. Org. Chem. 46 (1981) 3936
23. Baumgarten H.E., Smith H.L., and Staklis A. J. Org. Chem. 40 (1975) 3554
24. Borch R.F., Bernstein M.D., and Durst H.D. J. Am. Chem. Soc. 93 (1971) 2897
25. Anwer M.K., and Spatola A.F. Synthesis (1980) 929
26. 4 (5/95, v/v) (ca. pH7) = 5/95-95/5; Flow rate, 0.25 mL/min; Column temperature, 40 °C.The gradient program was as follows: initially A:B (5/95, v/v), then 8 min linear gradient to A:B (95/5, v/v) and 5 min isocratic with A:B (95/5, v/v); then an additional period of 7 min linear gradient to the initial conditions.